Skip to content

Effect of Re-education on Rebleeding Rate After Endoscopic Treatment in Liver Cirrhosis

Effect of Re-education on Rebleeding Rate After Endoscopic Treatment of Esophageal and/or Gastric Varices in Patients With Liver Cirrhosis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05302661
Enrollment
508
Registered
2022-03-31
Start date
2022-02-19
Completion date
2024-02-19
Last updated
2022-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding, Esophageal Varices Bleeding, Gastric Variceal Bleeding, Liver Cirrhosis

Brief summary

A prospective, randomized controlled study on whether re-education after discharge can reduce the rebleeding rate after endoscopic treatment of esophageal and gastric varices in patients with liver cirrhosis

Detailed description

After receiving esophageal variceal ligation and (or) gastric fundus variceal sclerotherapy, patients with outside hospitalthe rate of bleeding due to liver cirrhosis shall be re-educated outside the hospital, including diet, drugs, anticoagulation of portal vein thrombosis,regular endoscopic treatment, reexamination , nutrition, etc. The patients were divided into the first treatment group and the more thanonce treatment group according to whether they had received endoscopic treatment in the past

Interventions

BEHAVIORALre-education

Contact patients by phone or wechat and guide them

Sponsors

Qilu Hospital of Shandong University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Esophageal and / or gastric varices ; * liver cirrhosis ; * patients receiving endoscopic treatment (esophagogastric variceal sclerosis and/or ligation) ; * All subjects or their guardians must sign the subject consent form before entering the test

Exclusion criteria

* Patients with mental illness, severe hearing loss and unable to take care of themselves ; * ASA score ≥ grade IV at discharge ; * Hepatic encephalopathy ≥ stage II; * Patients with liver cancer; * Pregnant and lactating women; * Patients who cannot sign informed consent

Design outcomes

Primary

MeasureTime frameDescription
rebleeding2 yeasrebleeding from any channel can be followed up through medical institutions or telephone

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026